Luis Borges's most recent trade in Metagenomi Inc. was a trade of 291,450 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 1, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Metagenomi Inc. | Luis G. Borges | Chief Scientific Officer | 01 Apr 2024 | 291,450 | 291,450 | - | - | Stock Option (Right to Buy) | ||
| Metagenomi Inc. | Luis G. Borges | Chief Scientific Officer | 01 Apr 2024 | 69,316 | 69,316 | - | 0 | Common Stock | ||
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2023 | 7,452 | 0 | - | - | Stock Option (right to buy) | |
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.03 per share. | 03 Apr 2023 | 7,452 | 256,535 | - | 1.0 | 7,676 | Common Stock |
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.03 per share. | 21 Mar 2023 | 220,930 | 264,680 | - | 1.0 | 227,558 | Common Stock |
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2023 | 220,930 | 7,452 | - | - | Stock Option (right to buy) | |
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.03 per share. | 21 Mar 2023 | 65,698 | 109,448 | - | 1.0 | 67,669 | Common Stock |
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 3.72 per share. | 21 Mar 2023 | 65,698 | 43,750 | - | 3.7 | 244,640 | Common Stock |
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2023 | 65,698 | 228,382 | - | - | Stock Option (right to buy) | |
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.03 per share. | 21 Mar 2023 | 63,616 | 107,366 | - | 1.0 | 65,524 | Common Stock |
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 3.77 per share. | 21 Mar 2023 | 63,616 | 43,750 | - | 3.8 | 239,870 | Common Stock |
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2023 | 63,616 | 294,080 | - | - | Stock Option (right to buy) | |
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 3.55 per share. | 21 Mar 2023 | 15,597 | 249,083 | - | 3.5 | 55,369 | Common Stock |
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 131,250 | 131,250 | - | - | Stock Option (right to buy) | |
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 131,250 | 131,250 | - | - | Stock Option (right to buy) | |
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 21,875 | 43,750 | - | 0 | Common Stock | |
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 21,875 | 21,875 | - | 0 | Common Stock | |
| Century Therapeutics Inc | Luis Borges | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 105,000 | 105,000 | - | - | Stock Option (right to buy) |